Chronic kidney disease in type 2 diabetes mellitus: frequency, causes of development, eatures of hypoglycemic therapy
Author Affiliations1Novosibirsk State Medical University of Minzdrav of Russia, 630091, Novosibirsk, Krasny av., 52
2Novosibirsk State Medical University of Minzdrav of Russia, 630091, Novosibirsk, Krasny av., 52
3Novosibirsk State Medical University of Minzdrav of Russia, 630091, Novosibirsk, Krasny av., 52
4Novosibirsk State Medical University of Minzdrav of Russia, 630091, Novosibirsk, Krasny av., 52
Abstract
Chronic kidney disease (CKD) was found in 36.9 % cases among 2000 patients with type 2 diabetes mellitus examined on the basis of a mobile therapeutic and preventive module (Diamodul) in the districts of Novosibirsk region. The decrease in glomerular filtration rate (< 60 ml / (min × 1, 73 m2) was revealed in 20 % of patients. The primary cause of CKD in type 2 diabetes mellitus has hypertension and diabetic nephropathy; typical symptoms of diabetic nephropathy were detected in 22.6 % of patients. There was a correlation of GFR decline with increasing age of patients, duration of diabetes, high cholesterol and uric acid. Albuminuria level dependents on the duration of diabetes mellitus, glycated hemoglobin, triglycerides and uric acid. The presence of CKD C3a – C5 with type 2 diabetes significantly increased the incidence of CAD, stroke. Most patients with CKD did not reach the target values in the level of HbA1c, lipid and blood pressure and needed therapy change.
Key words
References
- Dobronravov V.A., Bystrova N.N., Drozdova Yu.V. Assessment of kidney dysfunction in diabetes mellitus patient // Nefrologiya = Nephrology. 2007. (11) №3. 7-11. [In Russian]
- Kobalava G.D., Villevaldе S.V., Ephremtseva M.A. Basics of cardiorenal medicine. Moscow: GEOTAR-Media, 2014. 256 p. [In Russian]
- Maslova O.V., Suntsov Yu.I., Shestakova M.V. et al. Prevalence of renal lesions in patients with type 1 and 2 diabetes mellitus in the Russian Federation // Sakharnyy diabet = Diabetes mellitus. 2009. (4). 48-51. [In Russian]
- Smyrnova A.V., Shilov E.M., Dobronravov V.A. et al. National recommendation. Chronic kidney disease : the basic principles of screening , diagnosis, prevention and treatment approaches // Nefrologiya = Nephrology. 2012. 16. (1). 89-115. [In Russian]
- Shamkhalova M.Sh., Yarek-Martynova I.R., Trubitsyna N.P., Shestakova M.V. Glucose-lowering therapies in patients with diabetes mellitus and chronic kidney disease // Sakharnyy diabet = Diabetes mellitus. 2013. (3). 97-102. [In Russian]
- Shestakova M.V., Dedov I.I. Diabetes mellitus and chronic kidney disease. Moscow: Meditsinskoe informatsionnoe agentstvo, 2009. 482 p. [In Russian]
- Shestakova M.V., Shamkhalova M.Sh., Yarek-Martynova I.Ya. et al. Diabetes mellitus and chronic kidney disease: achievements unresolved problems, and prospects for therapy // Sakharnyy diabet = Diabetes mellitus. 2011. (1). 81-88. [In Russian]
- Advance Collaborative Group, Patel A., MacMahan S., Chalmers J. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. 2008. 358. (24). 2560-2572.
- Astor B.C., Hallan S.I., Miller E.R. III et al. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population // Am. J. Epidemiol. 2008. 167. 1226-1234.
- Chan J.C., Scott R., Arjona Ferreira J.C. et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency // Diabetes Obes. Metab. 2012. 14. (11). 545-555.
- Gaede P., Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes // N. Engl. J. Med. 2008. 358. (6). 580-591.
- Iglesias P., Heras M., Diez J.J. Diabetes mellitus and kidney disease in the elderly // Nefrologia. 2014. 34. (3). 285-292.
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. 1998. 352. (9131). 837-853.
- Foley R.N., Murrey A.M., Li S. et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999 // J. Am. Soc. Nephrol. 2005. 16. 489-495.
- Kothny W., Shao Q., Groop P.H. et al. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment // Diabetes Obes. Metab. 2012. 14. (11). 1032-1039.
- Linnebjerg H., Kathare P.A., Park S. et al. Effect of renal impairment on the pharmacokinetics of exenatide // Br. J. Clin. Pharmacol.2007. 64. (3). 317-327.
- Lipska K.J., Bailey C.J., Inzucchi S.E. Use of metformine in the setting of mild-to-moderete renal insufficiency // Diabetes Care. 2011. 34. (6). 1431-1437.
- Macisaac R.J., Jerums G. Albuminuric and non-albuminuric pathways to renal impairment in diabetes // Minerva Endocrinol. 2005. 30. (3). 161-177.
- MacIsaac R., Panagiotopoulos S., McNeil K.J. et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? // Diabetes Care. 2006. 29. (7). 1560-1566.
- McGill J.B., Sloan L., Newman J. et al. Long-term efficacy and safety of linagliptin in patients with type2 diabetes and severe renal impairment: 1-year, randomized, double-blind, placebo-controlled study // Diabetes Care. 2013. 36. (2). 237-244.
- Nowicki M., Rychlik I., Haller H. et al. Saxagliptin improver glycemic control and is well toleretedin patients with type 2 diabetes mellitus and renal impairment // Diabetes Obes. Metab. 2011. 13. (6). 523-532.
- Salpeter S.R., Greyber E., Pasternak G.A., Salpeter E.E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus // Cochrane Database Syst. Rev. 2010. 14. (4). CD002967.
- Shurraw S., Hemmelgarn B., Lin M. et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study // Arch. Intern. Med. 2011. 171. (21). 1920-1927.
- Zinman B., Wanner C., Lachin J.M. et al. Empagliflozin, cardiovascular outcomes and mortality in Type 2 Diabetes // N. Engl. J. Med. 2015. 373. (22). 2117-2128.
About Authors (Correspondence):
Bondar I.A. – doctor of medical sciences, professor, head of the department of endocrinology, e-mail: bondaria@mail.ru
Zenkova E.V. – candidate of medical sciences, assistant professor of the chair of endocrinology, e-mail: elenazenkova@mail.ru
Krasnopevtseva I.P. – candidate of medical sciences, assistant professor of the chair of endocrinology, e-mail: k.i.p.@ngs.ru
Shabelnikova O.Yu. – candidate of medical sciences, assistant professor of the chair of endocrinology, e-mail: oushab@ngs.ru
